BME100 f2013:W900 Group12 L2

From OpenWetWare

Jump to: navigation, search
BME 100 Fall 2013 Home
People
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Photos
Wiki Editing Help
Image:BME494_Asu_logo.png


Contents

OUR TEAM

Name: Courtney Van Bussum)
Name: Courtney Van Bussum)
Name: Christopher Lae
Name: Christopher Lae
Name: Swathi Harikumar
Name: Swathi Harikumar
Name: Swaroon Sridhar
Name: Swaroon Sridhar
Name: Nhi Nguyen
Name: Nhi Nguyen
Name: student
Name: student

LAB 2 WRITE-UP

Descriptive Statistics

Experiment 1

Human Study Descriptive Statistics

Image:HumanDescriptiveStatisticsG12.png


Experiment 2

Rat Study Descriptive Statistics

Image:RatDescriptiveStatisticsG12.png






Results

Experiment 1




Image:Chart1.png

Experiment 2


Image:Chart2.png





Analysis

Experiment 1

Image:datatable.png Image:Lab2significance.png

Using the ANOVA test for the effect of LPS doses on Inflammotin levels in humans, we found that the p-value between groups was 1.4 x 10^-16, proving to be far below our .05 significance level. We can thus safely conclude that there is a significant statisical difference in Inflammotin levels between the groups of humans given different doses of the LPS drug.


Experiment 2

Image:datatablerats.png

Using the T-Test to determine the effect of LPS doses on Inflammotin levels in rats, we discovered that our P-value is 0.867403, which is greater than 0.05, which is not significant. Because of this there is no statistical difference in Inflammotin levels between the two groups of rats that were given different doses of the LPS drug.





Summary/Discussion

In Experiment One we observed the effect different doses of the inflammation inducing agent lipopolysaccharide (LPS) had on the amount of Inflammotin in the blood of humans. Through ANOVA, we determined there is indeed a statistically significant difference among all the dosages. This therefore provides support for our anticipated conclusion that increasing LPS doses increases the amount of inflammotin in the blood. In Experiment Two, in which inflammotin was measured in rats, the ELISA test revealed results that were not statistically significant. After performing a two sample t-test assuming equal variance, we found our p-value to be much higher than the accepted significance cut-off of 0.05. This evidence contradicts Kristen's assumption that LPS treatment in the rats significantly increased inflammotin levels. In conclusion, according to our study, LPS treatment in human subjects is a valid way to significantly increase inflammotin levels in the blood. In rats, however, LPS does not prove to be an effective treatment.







Personal tools